doi: 10.1016/j.clnu.2011.04.001
The result is reduced potency and potentially altered pharmacokinetics
Tirzepatide, on the other hand, is primarily used for the treatment of type 2 diabetes but has shown considerable potential for weight loss in clinical trials
With the aforementioned current legal backdrop, there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product as the market continues to evolve, even if the company has not historically focused on tirzepatide as a compound, Leerink analyst Michael Cherny wrote in the note
A newer medication, Tirzepatide, also addresses type 2 diabetes and obesity but offers a dual-action approach by combining GLP-1 receptor agonism with GIP activation
Individuals with restrictive eating disorders, fasting behaviors, or weight-driven purging may be at increased risk of symptom reactivation and are not appropriate candidates